Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity treatment benefits and costs.

The new platform lets employers offer GLP-1 drugs like Zepbound at a discounted rate while choosing from a marketplace of administrators.

Hernexeos is the second drug to secure an FDA approval under the agency’s priority voucher scheme, following in the footsteps of USAntibiotics’ Augmentin XR, which was granted the ticket in December ...

The Fred Hutch Postbaccalaureate Scholar Program is for individuals who would benefit from research experience and training to ensure that they are competitive when applying to biomedical PhD programs ...